| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | TREATMENTS FOR MYCOBACTERIUM TUBERCULOSIS | US14352440 | 2012-10-19 | US20140243255A1 | 2014-08-28 | Olga Kandror; Alfred Lewis Goldberg; Tatos Akopian; Eric J. Rubin; Ravikiran M. Raju |
| The technology described herein relates to treatments for tuberculosis which target the ClpP1P2 protease complex, including ClpC1. Further embodiments relate to assays and screens for modulators of the ClpP1P2 protease complex, including ClpC1. | ||||||
| 2 | Inhibition of ApoE cleavage activity in the treatment of ApoE-related disorders | JP2011537656 | 2009-11-20 | JP2012509888A | 2012-04-26 | チン シュ，; メイ シゥ スティール，; ヤトン ファン，; スティーブン バリー フリードマン，; ロバート ダブリュー． マハレイ，; カール エイチ． ワイスグレーバー， |
| 本発明は、ＡｐｏＥ関連障害を治療する方法を提供する、この方法は、全般的に、ＡｐｏＥを切断する酵素の活性を阻害する薬剤の有効量を投与するステップを含む。 | ||||||
| 3 | INHIBITION OF APOE CLEAVAGE ACTIVITY IN THE TREATMENT OF APOE-RELATED DISORDERS | EP09828290 | 2009-11-20 | EP2376090A4 | 2012-11-28 | HUANG YADONG; XU QIN; STEELE MEI XIU; MAHLEY ROBERT W; WEISGRABER KARL H; FREEDMAN STEPHEN BARRY |
| 4 | Treatments for Mycobacterium tuberculosis | US14352440 | 2012-10-19 | US09925251B2 | 2018-03-27 | Tatos Akopian; Olga Kandror; Alfred Lewis Goldberg; Ravikiran M. Raju; Meera Unnikrishnan; Eric J. Rubin |
| The technology described herein relates to treatments for tuberculosis which target the ClpP1P2 protease complex, including ClpC1. Further embodiments relate to assays and screens for modulators of the ClpP1P2 protease complex, including ClpC1. | ||||||
| 5 | METHODS AND ORGANISMS WITH INCREASED CARBON FLUX EFFICIENCIES | US15108259 | 2014-12-23 | US20160326553A1 | 2016-11-10 | Anthony P. BURGARD; Robin E. OSTERHOUT; Stephen J. VAN DIEN; Priti PHARKYA; Tae Hoon YANG; Jungik CHOI |
| The invention is directed to a non-naturally occurring microbial organism comprising a first attenuation of a succinyl-CoA synthetase or transferase and at least a second attenuation of a succinyl-CoA converting enzyme or a gene encoding a succinate producing enzyme within a multi-step pathway having a net conversion of succinyl-CoA to succinate. | ||||||
| 6 | Inhibition of ApoE Cleavage Activity in the Treatment of ApoE-Related Disorders | US13130003 | 2009-11-20 | US20120129782A1 | 2012-05-24 | Yadong Huang; Qin Xu; Mei Xiu Steele; Robert W. Mahley; Karl H. Weisgraber; Stephen Barry Freedman |
| The present invention provides methods for treating apoE-related disorders. The methods generally involve administering an effective amount of an agent that inhibits activity of an enzyme that cleaves apoE. | ||||||
| 7 | METHODS AND ORGANISMS WITH INCREASED CARBON FLUX EFFICIENCIES | EP14875558 | 2014-12-23 | EP3087174A4 | 2017-10-04 | BURGARD ANTHONY P; OSTERHOUT ROBIN E; VAN DIEN STEPHEN J; PHARKYA PRITI; YANG TAE HOON; CHOI JUNGIK |
| The invention is directed to a non-naturally occurring microbial organism comprising a first attenuation of a succinyl-CoA synthetase or transferase and at least a second attenuation of a succinyl-CoA converting enzyme or a gene encoding a succinate producing enzyme within a multi-step pathway having a net conversion of succinyl-CoA to succinate. | ||||||
| 8 | METHODS AND ORGANISMS WITH INCREASED CARBON FLUX EFFICIENCIES | EP14875558.0 | 2014-12-23 | EP3087174A2 | 2016-11-02 | BURGARD, Anthony P.; OSTERHOUT, Robin E.; VAN DIEN, Stephen J.; PHARKYA, Priti; YANG, Tae Hoon; CHOI, Jungik |
| The invention is directed to a non-naturally occurring microbial organism comprising a first attenuation of a succinyl-CoA synthetase or transferase and at least a second attenuation of a succinyl-CoA converting enzyme or a gene encoding a succinate producing enzyme within a multi-step pathway having a net conversion of succinyl-CoA to succinate. | ||||||
| 9 | INHIBITION OF APOE CLEAVAGE ACTIVITY IN THE TREATMENT OF APOE-RELATED DISORDERS | EP09828290.8 | 2009-11-20 | EP2376090A1 | 2011-10-19 | HUANG, Yadong; XU, Qin; STEELE, Mei Xiu; MAHLEY, Robert W.; WEISGRABER, Karl H.; FREEDMAN, Stephen Barry |
| The present invention provides methods for treating apoE-related disorders. The methods generally involve administering an effective amount of an agent that inhibits activity of an enzyme that cleaves apoE. | ||||||
| 10 | METHODS AND ORGANISMS WITH INCREASED CARBON FLUX EFFICIENCIES | PCT/US2014072178 | 2014-12-23 | WO2015100338A3 | 2015-09-03 | BURGARD ANTHONY P; OSTERHOUT ROBIN E; VAN DIEN STEPHEN J; PHARKYA PRITI; YANG TAE HOON; CHOI JUNGIK |
| The invention is directed to a non-naturally occurring microbial organism comprising a first attenuation of a succinyl-CoA synthetase or transferase and at least a second attenuation of a succinyl-CoA converting enzyme or a gene encoding a succinate producing enzyme within a multi-step pathway having a net conversion of succinyl-CoA to succinate. | ||||||
QQ群二维码
意见反馈
意见反馈